Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

UCHL1 inhibits cisplatin. 3 / 3

| 3

➶

reach

"Furthermore, UCHL1 expression level is negatively related to cisplatin resistance in ovarian cancer and knockdown of UCHL1 increased cisplatin resistance."

24155778

➶

reach

"Moreover, we have extended this finding to further experimentation and showed that knockdown of UCHL1 increased cisplatin resistance in both A2780 and IGROV1 ovarian cancer cells."

24155778

➶

reach

"For example, the level of UCHL1 is negatively related to cisplatin resistance in ovarian cancer, and knockdown of UCHL1 promotes cisplatin resistance."

33718207

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...

Other Services

This Service

This Project

IndraLab

Statements

UCHL1 inhibits cisplatin. 3 / 3

Our Sources:

Databases

Reading